Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018005716) ALBUMIN VARIANTS FOR ENHANCED SERUM HALF-LIFE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/005716 International Application No.: PCT/US2017/039857
Publication Date: 04.01.2018 International Filing Date: 29.06.2017
IPC:
C07K 14/765 (2006.01) ,C07K 14/76 (2006.01) ,C07K 14/435 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
76
Albumins
765
Serum albumin, e.g. HSA
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
76
Albumins
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
Applicants:
DENALI THERAPEUTICS INC. [US/US]; 151 Oyster Point Blvd., 2nd Floor South San Francisco, California 94080, US
Inventors:
DENNIS, Mark S.; US
KARIOLIS, Mihalis; US
SILVERMAN, Adam; US
Agent:
KAPLAN, Jonathan M.; US
Priority Data:
62/357,44301.07.2016US
Title (EN) ALBUMIN VARIANTS FOR ENHANCED SERUM HALF-LIFE
(FR) VARIANTS DE L'ALBUMINE POUR UNE DEMI-VIE SÉRIQUE AMÉLIORÉE
Abstract:
(EN) The present disclosure relates to albumin variants, derivatives and analogs thereof. In particular, provided are albumin variants that bind with increased efficiency to FcRn, including albumin variants that bind with increased efficiency at low pH levels but inefficiently or not at all at neutral pH levels. The albumin variants, derivatives, and analogs have an increased serum half-life when compared to naturally-occurring albumins.
(FR) La présente invention concerne des variants de l'albumine, leurs dérivés et leurs analogues. En particulier, l'invention concerne des variants de l'albumine qui se lient avec une efficacité accrue à FcRn, y compris des variants de l'albumine qui se lient avec une efficacité accrue à de faibles niveaux de pH mais inefficacement ou pas du tout à des niveaux de pH neutres. Les variants de l'albumine, les dérivés et les analogues ont une demi-vie sérique accrue par rapport aux albumines naturelles.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)